CN Patent

CN114907327A — Resmetirom的晶型及其制备方法和用途

Assigned to Hangzhou Lingye Pharmaceutical Technology Co ltd · Expires 2022-08-16 · 4y expired

What this patent protects

本发明涉及本申请涉及药物化学合成领域，公开了resmetirom的新晶型及其制备方法和用途，以及包含所述新晶型的药物组合物。本发明提供的resmetirom的新晶型制备方式简便、稳定性良好、吸湿性较低、粒度分布均匀、溶解度好，溶出度高，溶出快，符合药用要求，能稳定储存，具有很大的开发价值，有利于制备成制剂产品，适合工业化大生产。

USPTO Abstract

本发明涉及本申请涉及药物化学合成领域，公开了resmetirom的新晶型及其制备方法和用途，以及包含所述新晶型的药物组合物。本发明提供的resmetirom的新晶型制备方式简便、稳定性良好、吸湿性较低、粒度分布均匀、溶解度好，溶出度高，溶出快，符合药用要求，能稳定储存，具有很大的开发价值，有利于制备成制剂产品，适合工业化大生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN114907327A
Jurisdiction
CN
Classification
—
Expires
2022-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Lingye Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.